There are going to be many more mild to moderate Alzheimer’s patients…while a small trial might include PET etc to validate specificity, the post approval landscape and also likely in a clinical trial would incorporate a standardized cognitive assessment such as ADAScog.

https://pmc.ncbi.nlm.nih.gov/articles/PMC2744...erate%20AD.